Company Study of Huadong Medicine
  • May/2008
  • Hard Copy
  • USD $599
  • Pages:33
  • Single User License
    (PDF Unprintable)       
  • USD $599
  • Code:
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $1,200
  • Hard Copy + Single User License
  • USD $649
      

Huadong Medicine Co., Ltd. was founded in March, 1993, based on the medicine distribution network in Hanzhou, capital of Zhejiang province, after a government-oriented restructuring. On December 22, 1999, the company went public on the Shenzhen Stock Exchange and raised around CNY288 million through issuing 5,000 shares. Its main business covers the production and sale of chemical medicine and traditional Chinese medicine.

Structure of Main Business Revenue of Huadong Medicine


(Unit: CNY billion)
 
Source: ResearchInChina

Huadong Medicine's main business revenue covers two parts-pharmacy industry and pharmacy business. Since the gross profit margin of pharmacy industry is much higher than the pharmacy business, Huadong Medicine has been making vigorous efforts to open up the market of the pharmacy industry, which has made the proportion of its pharmacy industry to the total main business revenue increase year by year. This is one of the key reasons that the company's performance rose gradually in the recently years.

According to the company's announcement on April 3, 2008, Huadong Medicine plans to acquire 78.87% stake in Xi'an Bohua Pharmaceutical Co., Ltd. and 65% stake in the latter's subsidiary named Shaanxi Jiuzhou Medicine Co., Ltd. for CNY98 million. The acquisition, if done, will not only help the company reinforce its strength in special pharmaceutical raw materials, but also enter the narcotic market with high barriers to enter.

 

1. Huadong Medicine Company Profile
1.1 Brief Introduction
1.2 Shareholders of Huadong Medicine
1.3 Pharmacy Policies
1.3.1 Hospital to Follow the Measures for Prescription Management
1.3.2 Industry Concentration to Be Lifted Greatly by Improved Environment Protection Standards

2. Main Business of Huadong Medicine 
2.1 Products
2.2 Pharmacy Industry
2.2.1 Immunosuppressant Products
2.2.2 Diabetes Medicines
2.2.3 Anti-peptic ulcer medicine
2.2.4 Pharmaceutical Raw Material
2.2.5 Summery on Pharmacy Industry 
2.3 Pharmacy Business 
2.4 Marketing and Development Strategies
2.4.1 Marketing Strategy
2.4.2 Development Strategy

3. Financial Status of Huadong Medicine Co., LTD
3.1 Solvency 
3.2 Operation Efficiency
3.3 Profitability
3.4 Growing Ability
3.5 Financial Structure
3.6 Cash Flow Ratio

4. SWOT Analysis
4.1 Strength 
4.2 Weakness
4.3 Opportunities 
4.4 Threats

5. Summarization 


Huadong Medicine's Shareholding Structure 
Huadong Medicine's Organization Structure 
Huadong Medicine's Top Ten Shareholders As of 2007
Huadong Medicine's Main Products
Huadong Medicine's Main Businesses, 2003-2007
Huadong Medicine's Business Structure in 2007
Huadong Medicine's Gross Profit Margin, 2003-2007
Companies Producing Main Products of Huadong Medicine
Huadong Medicine's Sales Revenue by Product, 2007
Huadong Medicine's Sales Revenue of Main Products 
Huadong Medicine's Pharmacy Industry Performance, 1998-2007
Huadong Medicine's Distribution Targets in 2006 
Development Thought of the Western Medicine Sector
Huadong Medicine's Sales Revenue and Growth by Product, 2004-2008
Distribution of China Immunosuppressant Market Share
Purchasing Value of Sampled Immunosuppressant in Typical Cities of China
Growth Rate of Sampled Immunosuppressant in Typical Cities of China
Four Families in Cyclosporine Market
Immunosuppressant Markets in the U.S. and China
China Diabetes Market Scale and Its Growth, 2002-2006
Market Shares of Sampled Diabetes Medicines, 2005-2006
Market Shares of Pioglitazone Producers in 16 Chinese Sampled Cities
Top Ten Diabetes Medicine Producers in China, 2004-2006
Huadong Medicine's Revenue, Growth Rate and Profit Margin from Diabetes and Peptic Medicine, 2004-2008
Main Peptic Ulcer Drugs Applied in Clinic in China and their Market Shares
Proton Pump Inhibitor Main Products and Market Shares, 2004-2006
Pantoprazole Market Share and Growth, 2004-2006
Competition among Pantoprazole Producers
Competition among Omeprazole Producers
Huadong Medicine's Sales Revenue and Growth Rate, 2004-2008
Huadong Medicine's Specific Quality Standards for Bulk Raw Material Purchasing 
Growth of Huadong Medicine's Business 1998-2007
Huadong Medicine's Distribution Network
Huadong Medicine's Production, Sales, and Technical Team, 2006-2007
Products of General Agents above Designated Scale, 2005-2007
Ornidazole Applied for Gynecological Inflammation Disease, 2004-2006
Market Shares of Ornidazole
Huadong Medicine's Solvency
Huadong Medicine's Operation Efficiency 
Huadong Medicine's Profitability
Huadong Medicine's Growing Ability
Huadong Medicine's Financial Structure
Huadong Medicine's Cash Flows


China Blood Product Industry Report, 2020-2027

With the adjustment in the catalog of medicines covered by national medical insurance system, the scope and reimbursement ratio of almost all blood products for clinical use grow tremendously, which h...

China Medical Robot Industry Report, 2020-2026

Medical robot is the most promising segment of service robot market. By one estimate, globally 7,200 units of medical robots were sold and valued at $2.58 billion in 2019, compared with 5,100 units (u...

China In Vitro Diagnostic (IVD) Industry Report, 2019-2025

In vitro diagnosis (IVD) as a good way to make a rapid and definite diagnosis of diseases early, plays an increasingly crucial role in clinical medicine and related medical research fields. China’s IV...

China Aged Care Industry Report, 2019-2025

China’s society has aged before it gets rich. By the end of 2018, people aged over 60 had numbered 249.5 million in the country, or 17.9% of the total population, of which those aged over 65 were 167 ...

China Dental Industry Report, 2019-2025

Nowadays, the Chinese people have a growing awareness of oral health and healthy behaviors. 60.1% of residents have knowledge about oral health; 24.1% of 5-year-old children and 31.9% of 12-year-old c...

China Hospital Industry Report,2019-2025

The people’s growing awareness of health care and the acceleration of population aging have brought prosperity to China’s hospital industry. As of February 2019, there had been a total of 33,000 hospi...

China Dental Industry Report, 2017-2021

As living standards continue to improve and the awareness of oral health grows, consumers’ demand for dental services has kept increasing and the dental industry in China has witnessed robust developm...

China Interferon Industry Report, 2016-2021

Interferon is mainly used for the treatment of hepatitis B, hepatitis C, multiple sclerosis, condyloma acuminatum and other diseases. Wherein, IFN-α is mainly suitable for curing hepatitis B and hepat...

China Hospital Industry Report,2016-2020

In recent years, "Opinions on Promoting the Development of Health Service Industry" and other related policies, the people’s growing awareness of health care and the acceleration of population aging h...

China Aged Care Industry Report, 2016-2020

China entered the aging society early in 1999. By the end of 2015, China’s population aged over 60 reached 222 million and the old-age dependency ratio 13.9%. By 2020, China’s population aged over 60 ...

China Medical Robotics Industry Report, 2016-2020

Medical robotics can be used in surgery, rescue, transport, care, rehabilitation, dispensing and so on for the sick and wounded. Especially, surgical, rehabilitation and dispensing robots are the R &a...

China Dental Industry Report, 2016-2020

The dental industry refers to medical industrial chain on the basis of oral medical consumption, consisting mainly of dental apparatus (equipments and consumables), dental medical services, etc. With ...

China Medical Imaging Diagnosis Industry Report, 2015-2019

Against the background of a surge in social demand, handsome profit and the favorable opportunity brought by health care reform, the medical imaging industry, especially medical imaging equipment indu...

China Heparin Industry Report, 2015-2018

As the world's largest heparin API producer and exporter, China seizes about 80% share of the global heparin API market. After the explosive growth in 2008-2010, the stagnant international market and ...

Global and China Stem Cell Industry Report, 2015-2018

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Currently, stem cells are used to treat hund...

China Hospital Industry Report, 2015-2018

Stimulated by the demand, the number of hospitals in China rose from 21,979 in 2011 to 26,479 at the end of May 2015, an increase of 4,500 in total. Among them, public hospitals showed an overall decl...

China Independent Clinical Laboratory Industry Report, 2015-2018

The independent clinical laboratory originated from the U.S. and is relatively mature in developed countries/regions like North America, Europe, and Japan, whose independent clinical laboratory market...

China Medical Robot Industry Report, 2014-2018

Medical robots can be applied to surgeries, rescue, transport, nursing and rehabilitation of the sick and wounded. Wherein, surgery and rehabilitation robots are two striking market segments. Due to ...

2005- www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号